MinorGabapentinoids (antiepileptics)×Potassium-sparing diuretics (mineralocorticoid receptor antagonists)
Updated · Methodology
Mechanism
Pregabalin undergoes negligible metabolism: less than 2% of a dose appears in the urine as metabolites and the rest is excreted unchanged by the kidneys. It does not bind to plasma proteins and does not inhibit drug metabolism in vitro. According to its SmPC, it is unlikely to cause or be subject to pharmacokinetic interactions (pregabalin SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). A population pharmacokinetic analysis showed that diuretics had no clinically important effect on pregabalin clearance (pregabalin SmPC, EMA, section 4.5). Spironolactone undergoes extensive first-pass metabolism to canrenone and other partly active metabolites, which are eliminated in urine and bile (spironolactone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.2). Pregabalin is not among the drugs listed in the spironolactone SmPC.
Symptoms
The documents describe no symptoms caused by this combination. Pregabalin causes dizziness and somnolence, which can increase the risk of falls in older people. Loss of consciousness and confusion have been reported after marketing (pregabalin SmPC, European Medicines Agency, EMA, section 4.4). The main risk of spironolactone is raised blood potassium, especially in older people, in renal or hepatic impairment and with other potassium-raising drugs. Hyperkalaemia can be fatal (spironolactone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.4).
Management
According to the documents, the combination is acceptable and no dose change of spironolactone or pregabalin is needed. The pregabalin SmPC states that diuretics do not change its clearance, and the spironolactone SmPC does not name pregabalin (pregabalin SmPC, European Medicines Agency, EMA, section 4.5; spironolactone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). People taking pregabalin are advised to be careful until they know how it affects them. In renal impairment, the pregabalin dose is reduced according to creatinine clearance (pregabalin SmPC, EMA, sections 4.2, 4.4 and 5.2). With spironolactone, serum potassium and creatinine are checked one week after starting or increasing the dose, then monthly for the first 3 months, every 3 months until the end of the first year and every 6 months thereafter. Spironolactone is stopped temporarily or permanently if potassium exceeds 5 mmol/L or creatinine exceeds 220 micromol/L (spironolactone SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Espironolactona (nº registro 88191), sección 4.5 (2025)– AEMPS, CIMA, nº registro 88191, revisión 12/2025, sección 4.5
- EMA: Ficha técnica: Pregabalina (EU/1/04/279), secciones 4.4 y 4.5 (2024)– EMA, ficha técnica de Lyrica en CIMA (nº registro 104279015), revisión del texto 05/2024, secciones 4.4 y 4.5